News Helus shares slide on psychedelic readout in depression Helus has revealed data from a phase 3 trial of HLP003 that showed evidence of efficacy in depression, although its shares fell on safety concerns.
News Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.
News Definium chalks up new phase 3 win for LSD-based therapy Psychedelic drug developer Definium Therapeutics has reported positive phase 3 results with its LSD-based therapy, DT120, in anxiety.
News Lilly buys into psychedelics with $3.8bn AtaiBeckley deal AtaiBeckley has been snapped up by Eli Lilly in a massive $3.8bn transaction that shows psychedelic drugs are now firmly in the pharma mainstream.
News FDA grants three priority vouchers to psychedelics The FDA dropped a surprise Friday announcement that three more National Priority Vouchers would be given to a trio of psychedelics companies.
News Trump signs order to hasten psychedelic medicine access Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.